Alentis Therapeutics closes on USD 67m Series B Financing. The advisors
Walder Wyss acted as legal counsel to Alentis Therapeutics on the USD 67 million series B financing round. Morningside Venture Investments led the financing, joined by Jeito Capital and Series A investors Biomed Partners, BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund, High-Tech Gründerfonds and Schroders Capital.
Proceeds from the financing will be used primarily for proof-of-concept clinical trials of Alentis’ first-in-class, Claudin-1 targeting, anti-fibrotic molecules in advanced liver and kidney fibrosis, and support ongoing drug discovery programs targeting other fibrotic diseases and hepatobiliary cancers.
Jason Dinges, investment professional and IP counsel for Morningside and Rafaèle Tordjman, founder and CEO of Jeito Capital, also joined Alentis board of directors, effective immediately.
The Walder Wyss team was led by Alexander Gutmans (partner, corporate/m&a and venture capital, pictured) and included Markus R. Frick (partner, IP/IT), Manuel Bigler (senior associate IP/IT), Jessica Aeschbach Flórez (senior associate, corporate/m&a and notarial services), Karina Tschon (associate, corporate/m&a and venture capital) and Michelle Bruni (associate, tax).
Alentis Therapeutics is a Swiss biotech developing breakthrough treatments for fibrotic diseases.
